涩里番

Opportunities and challenges of the 2SLGBTQIA+ Community in RNA Research

Thursday, June 19, 2025 12:00to13:00

Join us for D2R鈥檚 Pride Month webinar: Opportunities and challenges of the 2SLGBTQIA+ Community in RNA Research on Thursday, June 19, from 12 to 1 pm EST./dna-to-rnaCategory:聽Research and innovation

Call for proposals: Master鈥檚 and Doctoral Scholar Awards

Published: 9 May 2025

D2R launches a call for applications for the Master鈥檚 and Doctoral Scholar Awards funding program....

Call for proposals: Foundational and Research in Motion

Published: 3 April 2025

D2R is pleased to launch the call for proposals for the Foundational and Research in Motion funding program....

D2R awards $10 million to accelerate RNA-based therapies for rare diseases and cancer

Published: 26 March 2025

Montreal, March 26, 2025 鈥 涩里番鈥檚 DNA to RNA Initiative (D2R) has awarded over $10 million in funding to support three groundbreaking research projects that will advance RNA-based...

涩里番 awards $500,000 to accelerate Mpox research and vaccine development

Published: 13 February 2025

Montreal, February 13, 2025 鈥 涩里番鈥檚 DNA to RNA Initiative (D2R) and 涩里番 Interdisciplinary Initiative in Infection and Immunity (MI4) have awarded $500,000 to fund five high-impact...

D2R awards over $6 million to support Core Platforms

Published: 7 February 2025

The D2R (DNA to RNA) Initiative has awarded more than $6 million to support eight Core Platforms at 涩里番 and one at the University of British Columbia through its Core Platform...

Industry Insights with etherna

Friday, January 31, 2025 12:00to13:30

On this page:聽/dna-to-rnaCategory:聽Research and innovation

D2R announces new round of funding, investing $1.5 million to advance research in RNA therapeutics and to support 涩里番 Centres and Institutes

Published: 19 December 2024

Montreal 鈥 December 19, 2024聽鈥 The D2R (DNA to RNA) Initiative is proud to announce the recipients of its latest round of funding, awarding a total of $1.5 million to four principal investigators...

Pages

Back to top